IP Seminar - Achieving Robust IP Protection of AI/ML Digital Health and Precision Medicine Innovation
Supporting the below United Nations Sustainable Development Goals:支持以下聯合國可持續發展目標：支持以下联合国可持续发展目标：
The rapid convergence of digital technologies with healthcare and life sciences over the past five years (even prior to the COVID-19 pandemic) has transformed how healthcare is delivered to the masses. The promise of digital technologies continues to transform the healthcare delivery model from the traditional, one-size-fits-all practice of medicine. IP protection for the kinds of innovation found in the digital health space is uncertain especially around the issue of patentable subject matter (section 101). We will discuss how to strategically build an IP portfolio around Digital Health innovation that can pass muster under section 101, provide a tutorial on how to invention sense in the Digital Health space and highlight how to leverage data rights protection to maximize its value.
Roger Kuan is the US head of the digital health and precision medicine practice and counsels companies that are uniquely positioned in the convergence of the life/medical sciences and technology industries on how to successfully navigate the complexities of the intellectual property (IP), data rights and regulatory challenges they encounter.
Roger has extensive experience in IP strategy and portfolio management (utility/design patents, trademarks, copyrights and trade dress), data rights strategy, licensing and technology transactions, freedom-to-operate clearances, enforcement, monetization, IP due diligence and dispute resolution. His practice is focused in the life sciences sector (e.g., research tools, analytical instrumentation/software, digital therapeutics, medical devices, diagnostics, biomanufacturing equipment, etc.) with an emphasis in emerging technologies such as Precision Medicine (e.g., genomic sequencing platforms, AI/ML, computational genomics/bioinformatics, molecular diagnostics, companion diagnostics, etc.), Digital Health (e.g., mobile apps, clinical decision support, software, digital therapeutics, AI/ML Imaging Diagnostics, wearables, etc.) and 3D printing/bioprinting.
Earlier in his career, Roger served as Director, IP Counsel at a multinational biotechnology company, where he managed a team to support the worldwide IP needs of the company's life sciences tools, bioproduction, molecular diagnostics and nucleic acid sequencing system/software platforms. Prior to finishing his law degree, he worked in the life sciences industry for several Fortune 500 pharmaceutical, medical device and chemical companies. He has held professional positions in the R&D, sales, engineering and regulatory affairs organizations.
Ms. Ms May WONG, ykwongmay@ust.hk